79,381 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Harvest Investment Services LLC

Harvest Investment Services LLC acquired a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 79,381 shares of the company's stock, valued at approximately $2,119,000. Harvest Investment Services LLC owned approximately 0.08% of Edgewise Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Summit Investment Advisors Inc. boosted its stake in Edgewise Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,594 shares of the company's stock worth $203,000 after acquiring an additional 482 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Edgewise Therapeutics by 1.7% during the fourth quarter. Alliancebernstein L.P. now owns 77,260 shares of the company's stock valued at $2,063,000 after purchasing an additional 1,300 shares during the last quarter. Diadema Partners LP bought a new stake in shares of Edgewise Therapeutics in the 4th quarter worth approximately $36,000. Rhumbline Advisers grew its stake in shares of Edgewise Therapeutics by 1.5% in the 4th quarter. Rhumbline Advisers now owns 102,397 shares of the company's stock worth $2,734,000 after buying an additional 1,525 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in Edgewise Therapeutics by 18.9% during the 4th quarter. Teacher Retirement System of Texas now owns 11,143 shares of the company's stock valued at $298,000 after buying an additional 1,772 shares in the last quarter.

Insider Transactions at Edgewise Therapeutics

In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,200 shares of the company's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $30.13, for a total value of $36,156.00. Following the completion of the sale, the insider now owns 14,863 shares in the company, valued at $447,822.19. This represents a 7.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin Koch sold 8,636 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $30.03, for a total value of $259,339.08. Following the completion of the transaction, the chief executive officer now directly owns 14,478 shares in the company, valued at $434,774.34. This trade represents a 37.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,836 shares of company stock worth $986,245 in the last quarter. Company insiders own 24.11% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on EWTX shares. Royal Bank of Canada dropped their target price on Edgewise Therapeutics from $56.00 to $52.00 and set an "outperform" rating on the stock in a report on Thursday, April 3rd. Stifel Nicolaus initiated coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They set a "hold" rating and a $30.00 price objective on the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $51.00 target price on shares of Edgewise Therapeutics in a report on Wednesday, April 2nd. Wedbush reiterated an "outperform" rating and set a $43.00 price target on shares of Edgewise Therapeutics in a report on Monday, April 21st. Finally, Scotiabank downgraded shares of Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and reduced their price target for the company from $50.00 to $14.00 in a research report on Wednesday, April 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Edgewise Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.13.

Edgewise Therapeutics Trading Down 3.6 %

EWTX stock traded down $0.56 on Friday, hitting $14.84. The company had a trading volume of 1,124,025 shares, compared to its average volume of 1,150,980. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.89 and a beta of 0.32. The stock's 50-day simple moving average is $20.32 and its 200 day simple moving average is $26.82. Edgewise Therapeutics, Inc. has a 12-month low of $10.60 and a 12-month high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.03). Research analysts forecast that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.